Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Brain Cancer treatment details. Biologic therapy. Chemotherapy. Radiation. Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland



Survival: 16.1 months
   
Toxicity Grade: 4
   
Treatments: Biologic therapy
Chemotherapy
Radiation
   
Drugs:
Country: Switzerland
   
City/State/Province: Lausanne
   
Hospital: Centre Hospitalier Universitaire Vaudois
   
Journal: Link
   
Date: 6/2010

Description:
Patients:
This study involved 52 patients with newly diagnosed glioblastoma. The median age of the patients was 57 years and 62% were male. Patients had not received prior chemotherapy or radiotherapy.

Treatment:
Patients were treated with a combination of radiotherapy, the chemotherapy agent temozolomide, and a biologic agent called cilengitide, which targets cellular proteins called integrins to inhibit cancer cell signaling and growth.

Toxicities:
The most common toxicity in this study was lymphocytopenia, and 56% patients experienced grade 3 or 4. Other grade 3 or 4 toxicities included thrombocytopenia (14% of patients), headache (6%), and fatigue (4%). There were no study-related deaths reported.

Results:
Median overall survival rate in this study was 16.1 months. Median progression-free survival was 8 months.

Support:
This study was supported by Merck, the company that manufactures cilengitide.

Correspondence: Dr. Roger Stupp; email: roger.stupp@chuv.ch

E-mail to a Friend Email Physician More Information